Evidence map›Paper›PMID 27555382›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation.

Andrew H Miller, Ebrahim Haroon, Jennifer C Felger

3 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 85 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 6 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03143075 nacompletednot on this map

Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?

TypeinterventionalSponsorRegion SkaneRan2017 to 2023Enrolled95ConditionsMajor Depressive DisorderArmsEicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day
NCT03966859 nacompletednot on this mapstarted 2019, after this paper: background citation

The Effect of Seven-Day Atorvastatin Administration on Emotional Processing, Reward Processing, and Inflammation in Healthy Volunteers

TypeinterventionalSponsorUniversity of OxfordRan2019 to 2020Enrolled50ConditionsHealthyArmsAtorvastatin 20mg, Lactose placebo
NCT05067777 phase2terminatednot on this mapstarted 2022, after this paper: background citation

Massage for Prostate Cancer-Related Fatigue (mPROSTATE)

TypeinterventionalSponsorUniversity of UtahRan2022 to 2025Enrolled28ConditionsProstate CarcinomaArmsSwedish Massage Therapy (SMT), Light Touch (LT) Control, Waitlist Control (WLC)
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 6 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  14. Trial
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Andrew H MillerDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Ebrahim HaroonDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-8817-1116
Jennifer C FelgerDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Emory University · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Inflammation-Induced CNS Glutamate as a Function of Depression in Middle AgeR01MH107033 · NIMH · EMORY UNIVERSITY · PI HAROON, EBRAHIM · 2016 to 2021
$2.2M
Phenotyping Major Depression with Increased InflammationR01MH087604 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H · 2010 to 2014
$2.2M
Inflammation Effects on Corticostriatal Connectivity and Reward: Role of DopamineR01MH109637 · NIMH · EMORY UNIVERSITY · PI FELGER, JENNIFER C · 2016 to 2019
$2.1M
Inflammation-Induced CNS Glutamate Changes in DepressionR01MH112076 · NIMH · EMORY UNIVERSITY · PI HAROON, EBRAHIM, MILLER, ANDREW H · 2016 to 2020
$2.0M
Dopaminergic Mechanisms of Cytokine-Induced Behavioral ChangeR01MH083746 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H · 2009 to 2012
$1.5M
Inflammation-Induced CNS Glutamate During Breast Cancer TreatmentR21MH105897 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H · 2015 to 2016
$429k
Neurobiology of cytokine effects on CNS glutamate in IFN-alpha-induced depressionR21MH106904 · NIMH · EMORY UNIVERSITY · PI FELGER, JENNIFER C · 2015 to 2016
$421k
Neurobiological and Behavioral Effects of Cytokine Antagonism in Major DepressionR21MH077172 · NIMH · EMORY UNIVERSITY · PI RAISON, CHARLES · 2008 to 2009
$379k
NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR002378NCI NIH HHS P30 CA138292NCRR NIH HHS UL1 RR025008NIMH NIH HHS R01 MH083746NIMH NIH HHS R01 MH087604NIMH NIH HHS R01 MH107033NIMH NIH HHS R01 MH109637NIMH NIH HHS R01 MH112076NIMH NIH HHS R03 MH100273NIMH NIH HHS R21 MH077172NIMH NIH HHS R21 MH105897NIMH NIH HHS R21 MH106904
6 · The paper itself

Abstract

A wealth of data has been amassed that details a complex, yet accessible, series of pathways by which the immune system, notably inflammation, can influence the brain and behavior. These data have opened the window to a diverse array of novel targets whose potential efficacy is tied to specific neurotransmitters and neurocircuits as well as specific behaviors. What is clear is that the impact of inflammation on the brain cuts across psychiatric disorders and engages dopaminergic and glutamatergic pathways that regulate motivation and motor activity as well as the sensitivity to threat. Given the ability to identify patient populations with increased inflammation, the precision of interventions can be further tuned, in conjunction with the ability to establish target engagement in the brain through the use of multiple neuroimaging strategies. After a brief overview of the mechanisms by which inflammation affects the brain and behavior, this review examines the extant literature on the efficacy of anti-inflammatory treatments, while forging guidelines for future intelligent clinical trial design. An examination of the most promising therapeutic strategies is also provided, along with some of the most exciting clinical trials that are currently being planned or underway.

Indexed as

AnimalsBrainHumansInflammationMental DisordersNeurotransmitter AgentsNeurotransmitter Agents

Identifiers

PMID27555382
PMCPMC5143492
OpenAlexW2507921187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.